Online Livestream
2nd Annual
2nd AnnualVirtual Clinical Trials
Event Overview

With growing pricing demands, increased regulatory scrutiny, patent expirations, and generic competition, it’s crucial that R&D departments are able to utilize digital technologies to ensure high-quality clinical trials. The industry is excited about virtual clinical trials, but the adoption curve is still light. As your organization prepares to apply novel technologies to clinical trials, whether they are fully-virtual or hybrid, it’s important to take into consideration how operational activities will perform when the trial is conducted virtually as opposed to a standard brick-and-mortar model.

Conceptualizing virtual trials not simply as a standard study, but as a way of doing things differently, is essential to a successful outcome. Join us to examine how the industry is navigating different models of remote trials and gain best practices for preparing or improving internal infrastructure to support a remote study.

Event Sponsors
New Topics
Featured Speakers
Alka Shaunik
Global Therapy Area Head, Cardiovascular & Metabolism, Medical Affairs
Amir Lahav
Digital Healthcare Innovation, Head of R&D Strategy
Anthony Costello
Senior Vice President of Mobile Health
Chris Reist
Medical Director, Psychiatry and Behavioral Science Science 37 Professor Emeritus, Department of Psychiatry and Human Behavior School of Medicine University of California- Irvine Research Psychiatrist Long Beach VA Healthcare System
Christoph Paul Vincent Hornik
Associate Professor of Pediatrics, Chief, Division of Quantitative Sciences
Duke Clinical Research Institute
Craig Lipset
Dr. Bola Oyegunwa
Vice President and Head of Virtual Trials
Glynn Dennis Jr.
Sr. Director, Data Science
Jacob LaPorte
Co-Founder & Global Head of The Novartis Biome, Chief Digital Office
Novartis Pharmaceutical Corporation
Jen Horonjeff
Patient Advocate, Founder and CEO
Jim Kremidas
Executive Director
Association of Clinical Research Professionals
John Reites
Josh Rose
VP & Global Head
IQVIA Virtual Trials
Karen Beyers
Director, Clinical Project Scientists
Johnson & Johnson
Kelly (Johnston) McKee
Head, Patient Recruitment
Vertex Pharmaceuticals
Kirsten Engelhardt
Associate Director, Applied Innovation & Process Improvement
Otsuka Pharmaceutical Companies (U.S.)
Kyle Faget
Foley & Lardner, LLP
Michelle Longmire
Co-Founder and CEO
Monica Chmielewski
Foley & Lardner, LLP
Nagaraja Srivatsan
Senior Vice President and Chief Digital Officer, Research and Development Solutions
Penny Randall
VP & Head, Central Nervous System (CNS) Center of Excellence
Reginald Hooks
Associate Director, Clinical Operations
Oncolytics Biotech
Sarah Krug
Executive Director
Shelly Barnes
Global Clinical Innovations
UCB Biosciences
T.J. Sharpe
Patient Advocate
Wendi Lau
Vice President, Operational Improvement & Reporting Excellence
Astellas Pharma
Yaritza Peña
Research Analyst, Tufts CSDD
Tufts University School of Medicine
Event Schedule

As we move through 2020, the industry will continue to incorporate digital health technologies into clinical study design. Leveraging technologies can improve recruitment, retention and give patients a choice of participating from home or site. Creating a more patient-friendly system is a process the industry is still attempting to solve. This session will discuss opportunities for improvements to virtual studies and examine how organizations are beginning to execute virtual designs.

  • Discuss how the industry is combining conventional strategies with virtual trials
  • Discuss when it can be more cost-effective to run a virtual clinical trial
  • Restructuring internal processes in order to implement a virtual trial
  • Investigate the digital health tools that can be utilized to move a virtual trial forward

Creating an experience that is less burdensome for patients is a top priority for the industry. Virtual trials can improve convenience for participants giving them broader options. This session will dive into a patient's experience with a virtual clinical trial, let’s discuss the burdens participants are still facing.

  • Explore the ease of using apps and devices in everyday life
  • Examine why the patient perspective is important in virtual trial design
  • Discuss what being monitored continuously is like through the patient perspective
  • What does data privacy mean to pharma vs. patients? Lack of provider engagement

Virtual clinical trials are not appropriate for every kind of clinical study. If a study requires complicated health measurements that require a trip to a clinic, a virtual study may not be a good option. How do you determine a good option for a virtual study and what companies are pushing forward with virtual trials? Explore trial selection and discover the best options for virtual studies.

  • Explore trial selection and discover the best options for virtual studies
  • Discover trials where capturing accurate and timely data through devices has been successful
  • Discuss patient needs and how much face-to-face interaction in necessary
  • Discuss new study designs (such as basket trials, adaptive trials, etc) and if they are amenable to virtual

Implementing new methods and technologies isn’t as easy as it sounds, new methods also bring new challenges. This talk will review successful case studies for evaluating new procedures and help bridge the gaps between conventional and virtual trials.

  • Review how companies are preparing to explore new digital solutions
  • Recognize strengths across different models and learn how teams are building their capabilities to align with new methods
  • Developing digital health strategy for using sensor technology in virtual trials
  • Understanding the value of incentivized strategies for patient engagement when using wearables and healthcare apps

When faced with tight regulation and balancing the adoption of new technology with patients’ best interests, it can be nerve-racking to push forward with virtual trial designs. This session will explore some of the big challenges that arise when considering new technology in clinical studies and how to overcome challenges to ensure the desired outcome.

  • Address concerns over data accuracy
  • Ensuring technology required works as it should
  • Discuss how organizations are being too conservative with their approach to virtual trials
  • Examine social and cultural barriers
  • Tufts CSDD studies have shown that complex protocols have a higher number of procedures associated with supplementary secondary, tertiary, and exploratory endpoints.
  • The results of the 2018 pilot study showed statistically significant associations observed between a composite measure of patient burden and protocol-specific design and performance measures, most notably study visits above the tolerable mean and the study conduct duration from first patient first visit to last patient last visit.
  • The study results also suggest a new and viable approach to optimize protocol design and improve patient engagement.
  • Discuss the organizational shift that sponsors need to make to support virtual clinical trials
  • Becoming more knowledgeable on how virtual trials are conducted and what data is most important to collect
  • Training employees on new topics and technologies
  • What skills sets must employees have?
Register Now

This window is secured by 256 bit encryption on a PCI compliant network. Click here to view this window in its own page.

Subscribe to Conference Updates
Join our e-newsletter list to follow closely all news.
Event Partners
Contact Us